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Abstract
Background: The presence of additional chronic conditions has a significant impact on the treatment and management
of type 2 diabetes (T2DM). Little is known about the patterns of comorbidities in this population. The aims of this study
are to quantify comorbidity patterns in people with T2DM, to estimate the prevalence of six chronic conditions in 2027
and to identify clusters of similar conditions.
Methods: We used the Clinical Practice Research Datalink (CPRD) linked with the Index of Multiple Deprivation (IMD) data
to identify patients diagnosed with T2DM between 2007 and 2017. 102,394 people met the study inclusion criteria. We
calculated the crude and age-standardised prevalence of 18 chronic conditions present at and after the T2DM diagnosis.
We analysed longitudinally the 6 most common conditions and forecasted their prevalence in 2027 using
linear regression. We used agglomerative hierarchical clustering to identify comorbidity clusters. These analyses
were repeated on subgroups stratified by gender and deprivation.
Results: More people living in the most deprived areas had ≥ 1 comorbidities present at the time of diagnosis (72%
of females; 64% of males) compared to the most affluent areas (67% of females; 59% of males). Depression prevalence
increased in all strata and was more common in the most deprived areas. Depression was predicted to affect 33%
of females and 15% of males diagnosed with T2DM in 2027. Moderate clustering tendencies were observed, with
concordant conditions grouped together and some variations between groups of different demographics.
Conclusions: Comorbidities are common in this population, and high between-patient variability in comorbidity
patterns emphasises the need for patient-centred healthcare. Mental health is a growing concern, and there is a need
for interventions that target both physical and mental health in this population.
Keywords: Comorbidity, Type 2 diabetes mellitus, CPRD, Prevalence, Primary care
Background
The prevalence of type 2 diabetes (T2DM) is increasing
in the UK and internationally. Diabetes (all types) is esti-
mated to affect 1 in 11 adults aged 20 to 79 years, or 415
million adults globally [1]. In 2016, it was the seventh
leading cause of death worldwide with an estimated 1.6
million deaths directly caused by diabetes [2]. In the UK
over 90% of diabetes cases are type 2 diabetes [3], with
most individuals having at least one other chronic condi-
tion [4]. Diabetes-related healthcare outcomes, treat-
ment options, care needs and associated cost are
complicated by the presence of comorbidities—chronic
conditions existing in addition to T2DM.
Due to similar risk factors, such as obesity, endothelial
dysfunction, vascular inflammation and dyslipidaemia [5],
people with T2DM have higher risks of cardiovascular
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complications [6], end-stage renal disease [7] and hyper-
tension [8]. However, individuals with T2DM have also
been found to have higher risks of depression [9], thyroid
gland diseases [10] and chronic obstructive pulmonary
disease (COPD) [11]. People with multiple chronic condi-
tions report a number of barriers to self-care such as
physical limitations, lack of knowledge, financial con-
straints, logistics of obtaining care and the need for social
and emotional support [12]. The specific combination of
comorbidities in diabetes (type 1 and 2) patients has been
found to impact their ability to prioritise and manage the
disease [13]. Patients with conditions considered unrelated
to diabetes may need additional support in making deci-
sions about care priorities and self-management activities
[13]. While the presence of diabetes-“concordant” condi-
tions (i.e. sharing the same management goals), tends to
be positively associated with quality of care [14], certain
“discordant” comorbidities, like depression and arthritis,
impact on treatment options, posing barriers to lifestyle
changes and self-care behaviours recommended for dia-
betes management [14–16].
The specific combinations of conditions present dic-
tate the needs of patients, management priorities and
the associated demand on healthcare services [17]. A
better understanding of the nature, prevalence and pat-
terns of comorbidities in T2DM patients may provide
key insights for managing patients with multiple condi-
tions in primary care and facilitate a more patient-
centred approach in risk assessment and more appropri-
ate and tailored therapeutic interventions. Understand-
ing and forecasting the prevalence of specific
comorbidities can inform policy-makers in planning and
structuring health services to meet the future demands
of the population.
In this study, we explored the comorbidities’ patterns
occurring in patients with T2DM over time, as seen in
English primary care. We quantified the prevalence of
18, highly prevalent and well-recorded physical and
mental health conditions and compared the patterns in
subgroups of patients stratified by gender, age and socio-
economic deprivation. Focusing on an incidental cohort
of patients with T2DM, we explored the patterns in co-
morbidity occurrence at the time of T2DM diagnosis
and after 2, 5and 9 years of follow-up.
Methods
Data source
The Clinical Practice Research Datalink (CPRD) is a data-
base of anonymised electronic, primary health records. In
January 2017, the CPRD held data on nearly 17 million ac-
tive and historical patients registered with 714 general
practices across the UK. It contains information on diag-
noses, referrals, tests and therapy records, which are
mainly recorded using Read clinical codes. Additional data
is available for a subset of English practices (nearly 75% of
English practices; 58% of all UK CPRD practices) which
consented to participate in the CPRD linkage scheme and
provided patient-level information. To obtain information
on social deprivation at the level of the patient’s postcode,
we used the linked information on the quintiles from the
2015 Index of Multiple Deprivation (IMD) measure,
which aggregates data on income, employment, health
and disability, education and training, barriers to housing
and services, crime and living environment.
Study sample
People registered with a general practice in England
meeting CPRD data quality standards and with the first
T2DM Read code recorded at any point between 1 April
2007 and 31 March 2017 were included. The inclusion
criteria for this study were as follows: patient registered
with a CPRD practice for at least 365 days before T2DM
diagnosis, aged 35 years and older and no recorded diag-
nostic code for type-1 diabetes mellitus. In the UK,
T2DM has been incentivised since 2004 through a na-
tional pay-for-performance scheme, the Quality and
Outcomes Framework (QOF), along with another 20
clinical domains approximately, resulting in uniformity
in Read code usage and recording. The index date was
defined as the date of first recorded code for T2DM and
the follow-up as the time between the index date and
the earliest of date of death, transfer out of practice date
and last date of data collection from the practice or the
end of study period (31 March 2017). The lists of codes
used to establish the presence of each comorbidity were
downloaded from clinicalcodes.org and CPRD@Cam-
bridge websites.
Defining comorbidities
We selected the following 18 conditions: coronary heart
disease (CHD), chronic kidney disease (CKD), atrial fib-
rillation, stroke, hypertension, heart failure, peripheral
vascular disease (PVD), rheumatoid arthritis, cancer,
osteoporosis, depression, asthma, chronic obstructive
pulmonary disease (COPD), dementia, severe mental ill-
ness (SMI), epilepsy, hypothyroidism and learning dis-
ability. The reporting of these conditions is financially
incentivised under the QOF, and consequently, they are
well-recorded in the CPRD. The presence of asthma,
epilepsy and depression was determined using Read
codes and prescription data, since these can be acute or
resolvable. Each condition was considered to be present
at the index date if it satisfied the definition criteria at
the time of the T2DM diagnosis (Additional file 1: Table
S1). Each condition was considered to be present during
the follow-up period if it satisfied the definition criteria
at the index date or at any time during the follow-up.
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Statistical analysis
First, we used the sample in terms of the total num-
ber of comorbidities present at the index date and
after 1 year, 5 years and 9 years of follow-up. We ex-
amined the total number of comorbidities present at
and after the index date, stratified by gender and so-
cial deprivation quintiles. Age-standardised prevalence
was calculated using the direct age standardisation to
the 2013 European Standard Population using 5-year
age bands up to 95+ years old. Differences between
means of categorical variables were tested using 2-
sample t tests.
We calculated the age-standardised prevalence of each
condition, stratified by gender, for patients from the least
and most deprived areas. We also calculated the crude
and age-standardised co-prevalence of each pair of co-
morbidities for the whole sample and stratified by gen-
der, deprivation (least and most deprived areas) and age
(using 35–54-, 55–74- and 75+-year-old age bands).
We longitudinally calculated the prevalence of each
comorbidity present at the time of the T2DM diagnosis
in the incidental cohort of patients with T2DM, for fi-
nancial years (April to March) 2007/2008 to 2016/2017.
To forecast the proportion of people diagnosed with
T2DM in the next 10 years that will also have a particu-
lar comorbidity present at the time of diagnosis, we used
linear regression on log-transformed, age-standardised
prevalence. For clarity of results, we present the patterns
for the six most prevalent conditions as the prevalence
of remaining conditions remained relatively low and
stable over the study period.
Lastly, we selected patients with two or more comor-
bidities present at the index date and used agglomerative
hierarchical clustering to identify groups of similar con-
ditions. Similarity was assessed using the tetrachoric cor-
relation coefficient. Tetrachoric correlation estimates
what the correlation for two binary variables would be if
they were measured on a continuous scale. We used
Ward’s linkage method to group conditions. At each
linkage step, Ward’s method finds a pair of clusters that
leads to a minimum increase in total within-cluster vari-
ance after merging. To avoid chaining (low prevalence
comorbidities being sequentially linked to existing clus-
ters), we excluded conditions with prevalence in a given
group below 3%. Cluster analysis was stratified by gen-
der, age bands (35 to 54 years, 55 to 74 years and ≥ 75
years old) and deprivation using the least and most de-
prived quintiles. We present the results for the whole
sample. Stratified results are available in Additional file 1:
Figure S12–S18. To assess the progression in clustering
patterns, we performed the cluster analysis for condi-
tions present at the time of T2DM diagnosis and those
present at 2, 5 and 9 years after. We plotted the results
in dendrograms and identified clusters using visual
analysis. Dendrograms visually represent the clustering.
The heights at which conditions fuse together corres-
pond to their similarity. The earlier the branches merge,
the more similar the groups of conditions are. The clus-
tering structure was measured using the agglomerative
coefficient, with values closer to zero suggesting tight
clustering of objects and values closer to one suggesting
less well-formed clusters. Due to differences in sample
sizes, agglomerative coefficients should not be compared
across groups. We used R version 3.4.2 for the analysis
and data preparation.
Results
We identified 102,394 people with incident T2DM dur-
ing the study period, who met the study inclusion cri-
teria. A flow chart of the data cleaning process is
available in Additional file 1: Figure S1. The median
(LQ, 25th centile; UQ, 75th centile) follow-up was 4.9
years (LQ, 2.8; UQ, 7.3). Over half of the sample (56.3%)
was male with an average (mean ± standard deviation)
age at diagnosis of 60.3 (± 12.5) (Table 1). On average,
women were diagnosed at an older age (63.7 ± 13.6, p <
0.001) and had more comorbidities at the time of T2DM
diagnosis compared to males (1.6 ± 1.4 vs 1.2 ± 1.2, p <
0.001). People from the most deprived areas were diag-
nosed with T2DM at a younger age, compared to those
from the most affluent areas (59.3 ± 13 vs 63.9 ± 12.8,
p < 0.001). The age-standardised prevalence of one or
more comorbid conditions was 33.3% (95% confidence
interval: 32.5%; 34.1%) for the least deprived areas and
32.7% (31.7%; 33.3%) for the most deprived areas (Fig. 1)
. For four or more comorbid conditions, the age-
standardised prevalence was 2.9% (2.7%; 3.1%) in the
most affluent areas and 4.4% (4.1%; 4.7%) in the most
deprived areas. In all subgroups (by sex and deprivation),
the proportion of people with zero comorbidities de-
creased during the follow-up period (Fig. 1).
Hypertension was the most common condition among
all patients, with higher prevalence among females than
males (42.8% [42.3–43.3%] vs 45.8% [45%; 46.4%]) (Fig. 2,
crude prevalence Additional file 1: Figure S2). In fe-
males, the second most prevalent condition was depres-
sion, with higher prevalence in females from the most
deprived areas (20.2% [19.3%; 21.1%]), than from most
affluent areas (15.6% [14.7%; 16.5%]). In males, the sec-
ond most prevalent condition was CHD with higher
prevalence among males from the most deprived areas
(13.6% [12.9%; 14.3%]), than from the most affluent
areas (10.8% [10.3%; 11.3%]). During follow-up, the
prevalence of depression and asthma decreased in all
groups whereas the prevalence of all other conditions’
increased (prevalence rates for SMI, dementia, epilepsy
and learning disability was too low to make meaningful
comparisons) (Additional file 1: Figure S3). Hypertension
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and CKD had the highest age-standardised co-
prevalence rate among all patients, at 12.1% at the time
of T2DM diagnosis and 15.4%, 17.8% and 21.5% after 2,
5 and 9 years from the T2DM diagnosis (Additional
file 1: Figure S4–S11).
Our longitudinal analysis showed a steady decrease in
the prevalence of hypertension and relatively stable
prevalence rates for CHD, CKD, stroke and atrial fibrilla-
tion (Fig. 3). The prevalence of depression increased
during the study period for all analysed groups. In fe-
males, the age-standardised prevalence rate of depres-
sion increased from 15.9% (95% CI 14.8%; 17.0%) in
2007 to 21.5% (19.7%; 20.8%) in 2015 and 18.8% (16.8%;
20.8%) in 2016. In males, the age-standardised preva-
lence rate of depression increased from 7.0% (3.4%;
7.6%) in 2007 to 10.4% (9.1%; 11.7%) in 2016. If the
current trend continues, depression can affect over a
third of females diagnosed with T2DM by 2026 (age-
standardised prevalence, 30.7% [23.9%; 39.4%]) and over
15% (13.2%; 18.9%) of males. The prevalence of depres-
sion increased from 9.8% (8.5%; 11.1%) in 2007 to 14.9%
(11.3%; 16.5%) in 2016 in the most affluent areas. In the
most deprived areas, it increased13.4% (12.0%; 14.8%) in
2007 to 17.7% (15.3%; 19.6%) in 2015 and to 14.1%
(11.5%; 16.7%) in 2016. If current trend continues,
depression is predicted to affect 17.9% (11.7%; 27.5%) of
people in the most affluent and 21% (15.9%; 29.5%) of
people from the most deprived areas by 2026.
The hierarchical cluster analysis showed conditions
being grouped into two main clusters: the first com-
posed of atrial fibrillation, heart failure, PVD, CHD,
cancer, stroke, hypertension and CKD and the second
composed of depression, SMI, COPD, asthma,
hypothyroidism, rheumatoid arthritis and osteoporosis
(Fig. 4). This pattern was similar in all analysed
groups with cancer being included in the first cluster
for males, people from the most deprived areas,
people age 35 to 74 and 75 and over (Additional file 1:
Figure S12–S18). However, cancer was linked with
cluster two in females, people from the least deprived
areas and people age 55–74. Moderate clustering ten-
dencies have been observed for conditions present at
the time of T2DM diagnosis with the agglomerative
coefficient around 0.45 with some variations between
groups.
Discussion
Summary
We showed important changes in the comorbidity pat-
terns in a large real-world cohort of people living with
Table 1 Descriptive statistics on patients with type 2 diabetes mellitus (type 2 diabetes) and additional comorbidity
N (%) Age
(mean ± SD)
Follow-up
period (median
(LQ; UQ))
Number of
comorbidities at
T2DM diagnosis
(mean ± SD)
Number of comorbidities
2 years after T2DM
diagnosis (mean ± SD)
(sample surviving 2 years)
Number of comorbidities
5 years after T2DM
diagnosis (mean ± SD)
(sample surviving 5 years)
Number of comorbidities
9 years after T2DM
diagnosis (mean ± SD)
(sample surviving 9 years)
Total cohort 102,394
(100)
62.1 ± 13.1 4.9 (2.8; 7.3) 1.4 ± 1.3 1.5 ± 1.4 (84,350) 1.6 ± 1.4 (50,475) 1.7 ± 1.4 (8977)
Gender
Females 44,764
(43.7)
63.7 ± 13.6 4.9 (2.7; 7.3) 1.6 ± 1.4 1.7 ± 1.4 (36,669) 1.8 ± 1.4 (21,830) 1.9 ± 1.5 (3942)
Males 57,630
(56.3)
60.7 ± 12.5 5 (2.8; 7.3) 1.2 ± 1.2 1.4 ± 1.3 (47,681) 1.5 ± 1.3 (28,645) 1.6 ± 1.4 (5035)
Age bands
35–54 years 31,545
(30.8)
46.8 ± 5.2 5.1 (2.9; 7.4) 0.8 ± 0.9 0.9 ± 1 (26,368) 1 ± 1 (16,106) 1.1 ± 1 (2893)
55–74 years 51,288
(50.1)
64.2 ± 5.6 5.2 (3; 7.5) 1.4 ± 1.2 1.6 ± 1.3 (42,950) 1.7 ± 1.3 (26,618) 1.9 ± 1.4 (4871)
75+ years 19,561
(19.1)
81 ± 4.9 4.1 (2.1; 6.5) 2.3 ± 1.6 2.5 ± 1.6 (15,032) 2.6 ± 1.6 (7751) 2.8 ± 1.5 (1213)
IMD quintiles
Quintile 1—least
deprived
19,110
(18.7)
63.9 ± 12.8 5 (2.8; 7.3) 1.3 ± 1.3 1.5 ± 1.3 (15,756) 1.6 ± 1.4 (9574) 1.7 ± 1.4 (1682)
Quintile 2 20,722
(20.2)
63.4 ± 13 5.1 (2.8; 7.4) 1.4 ± 1.3 1.5 ± 1.3 (17,223) 1.6 ± 1.4 (10,500) 1.7 ± 1.4 (1878)
Quintile 3 21,572
(21.1)
62.7 ± 13 4.9 (2.8; 7.3) 1.4 ± 1.3 1.5 ± 1.3 (17,811) 1.6 ± 1.4 (10,605) 1.8 ± 1.4 (1884)
Quintile 4 21,393
(20.9)
61 ± 13.2 4.9 (2.7; 7.2) 1.4 ± 1.3 1.5 ± 1.4 (17,489) 1.7 ± 1.4 (10,334) 1.7 ± 1.4 (1839)
Quintile 5—most
deprived
19,597
(19.1)
59.3 ± 13 4.8 (2.7; 7.3) 1.4 ± 1.4 1.6 ± 1.4 (16,071) 1.7 ± 1.4 (9462) 1.7 ± 1.4 (1694)
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Fig. 1 Age-standardised and crude prevalence of multiple conditions in patients with T2DM. Age-standardised (top) and crude (bottom)
prevalence of zero, one, two, three and four or more comorbidities present in patients with type 2 diabetes at the time of type 2 diabetes
diagnosis and after 2, 5 and 9 years of follow-up. Stratified by gender and deprivation. T2DM - type 2 diabetes mellitus; Dx - diagnosis; IMD -
Index of Multiple Deprivation
Fig. 2 Age-adjusted prevalence of chronic conditions among patients with T2DM. Age-adjusted prevalence of chronic conditions among females
and males with type 2 diabetes from the least and most deprived areas at the time of type 2 diabetes diagnosis. IMD - Index of Multiple Deprivation;
CHD - coronary heart disease; CKD - chronic kidney disease; COPD - chronic obstructive pulmonary disease; PVD - peripheral vascular disease; SMI -
severe mental illness
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T2DM, using data from the UK primary care. Our find-
ings are relevant to patients, clinicians and policy-
makers and can inform on the healthcare needs and how
best to prioritise and deliver care for people with T2DM.
We identified alarming levels and trends of depression
prevalence, which we estimated will continue to grow
over the next decade. This could have major conse-
quences for how to offer these patients integrated care.
Health systems will have to respond to a growing need
for diagnosis and management of mental health prob-
lems among people with T2DM, underpinned with
established links between depression and poor glycaemic
control [18], treatment adherence [19], diabetes compli-
cations [9] and mortality [20]. The differences in comor-
bidity patterns observed in groups stratified by gender
and social deprivation highlight the need to address the
present and increasing health inequalities, particularly
with higher prevalence of comorbidities in patients from
more deprived areas.
Strengths and limitations of the study
To the best of our knowledge, this is the largest study of
comorbidities in patients with T2DM in England. The
quality of the data is very high for our study period, pri-
marily due to data recording in line with the QOF and
the financial incentives offered to UK primary care for
the management of chronic and other conditions such
as T2DM.
However, the study has limitations. First, due to the
low prevalence of some conditions in general and in spe-
cific groups, some comorbidities were excluded from the
cluster analysis for all or some strata. However, all con-
ditions were included in the frequency analysis which
provides a starting point for the analysis of grouping pat-
terns of specific conditions. Second, we selected only 18
conditions for which recording quality was high, but pa-
tients may have additional comorbidities impacting on
their disease management and quality of life. Third,
some of these comorbidities, like CKD and CHD, are
Fig. 3 Observed and predicted prevalence of selected conditions in patients with T2DM. Observed and predicted prevalence of selected
conditions present at the time of type 2 diabetes mellitus (type 2 diabetes) diagnosis stratified by gender (a, b) and deprivation (c, d). IMD -
Index of Multiple Deprivation; CHD - coronary heart disease; CKD - chronic kidney disease; COPD - chronic obstructive pulmonary disease; PVD -
peripheral vascular disease; SMI - severe mental illness
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closely linked to T2DM, to the extent of them being
considered its complications. However, the majority of
patients with these conditions do not have T2DM, while
the characterisation of these conditions is immaterial to
our analyses. Fourth, to identify patients with depression,
we used an algorithm analysing prescriptions as well as
diagnostic codes. We were unable to discriminate uses
of antidepressants for other conditions such as
obsessive-compulsive or bipolar disorders; therefore, pa-
tients with other mental health conditions might have
been incorporated into the depression group. Fifth, the
predictions of future prevalence rates were obtained
from linear regression models, which are dependent on
certain assumptions such as the linearity of the trend.
Sixth, some of the conditions we modelled may be
present but undiagnosed in our cohort. Seventh, for the
hierarchical clustering, each comorbidity is necessarily
considered into a single cluster, which may not be the
case [21]. Last, some diagnostic criteria were also chan-
ged during the study period, for example, the diagnostic
criteria for hypertension. Therefore, the average number
of comorbidities calculated in our sample is likely to be
underestimated both due to the finite set of conditions
we used and to non-diagnosis in practice.
Comparison with existing literature
We found that almost 75% of patients had at least one
additional comorbidity at the time of T2DM diagnosis
and 44% had at least two comorbidities. Prevalence of
multiple conditions in addition to T2DM was lower than
that reported in some clinical trials (90%) [22] or studies
using administrative data (91.4%) [23] (84.6%) [24] but
higher than in others (44%) [25]. However, our popula-
tion was younger than in some studies, and we analysed
a large but not exhaustive list of conditions. As expected,
the burden of comorbidity increased with age, however,
contrary to previous research [4, 8], which found a
higher age-standardised prevalence of coexisting comor-
bidities in males or no gender difference, we found that
the burden was higher in females. This reflects the pat-
tern in the general population which shows that females
tend to have more comorbid conditions than males [26].
Fig. 4 Cluster analysis of comorbidities in people with type 2 diabetes. Cluster analysis of comorbidities in people with type 2 diabetes at the
time of the diagnosis (a), 2 (b), 5 (c) and 9 (d) years after. CHD - coronary heart disease; CKD - chronic kidney disease; COPD - chronic obstructive
pulmonary disease; HP - hypothyroidism; PVD - peripheral vascular disease; SMI - severe mental illness
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This difference may relate to the surveillance bias with
females being more likely to visit a general practitioner
and therefore have a recorded diagnosis of comorbidity.
In addition, previous studies tend to focus on conditions
regarded as diabetes-concordant such as cardiovascular
diseases and CKD [4]. Females with T2DM were found
to have a lower probability of these having conditions
and a higher prevalence of depression, which we in-
cluded in our study [23]. The presence of mental health
problems may have a significant impact on the ability of
the patient to manage their condition, progression of
T2DM [8, 16, 18]. Our findings of the high and increas-
ing prevalence of depression in patients with T2DM
imply that the inclusion of mental health conditions is
essential in studies of comorbidities in this population.
We found that the prevalence of all conditions except
asthma and depression increased after diagnosis of
T2DM. The fall in the prevalence of treated asthma dur-
ing the follow-up may be related to the correlation
between metformin use and decrease in asthma exacer-
bation [27]. Knowing that T2DM is highly correlated
with obesity, as is asthma [28] and depression [29], it
may be that patients after being diagnosed with T2DM
work towards lowering their BMI, and therefore, both
conditions may be resolved.
We observed a higher burden of comorbidity among
people from the most deprived than the most affluent
areas. Differences were also observed in the prevalence
of specific conditions, notably higher prevalence of de-
pression, CHD, asthma and COPD among people from
the most deprived areas. This is consistent with other
studies and may be explained by the higher prevalence
of risk factors such as smoking, obesity and alcohol con-
sumption [30, 31].
We found a very large increase in the prevalence of
T2DM-comorbid depression, which is expected to rise
over the next 10 years. The rising prevalence of depres-
sion and the large gender gap has also been observed for
the general population [32]. There is an ongoing discus-
sion over whether antidepressants are overprescribed
[33, 34] which could explain the rise in depression ob-
served in our analysis. Furthermore, the data may repre-
sent rises in conditions other than depression such as
chronic pain for which antidepressants can be prescribed
[35]. Although this discussion is inconclusive, the rise in
antidepressant use in patients with T2DM should be a
concern, with some evidence proposing that some anti-
depressants may be an independent risk factor for
T2DM [36], suggesting that both conditions share simi-
lar risk factors. More research is needed to provide fur-
ther insight into the increase in depression and
antidepressants use in patients with T2DM. Neverthe-
less, people with both T2DM and depression may
require tailored approaches of treatment for both
conditions as depression was found to impair patients’
ability to manage their diabetes [15].
The observed and predicted stable or decreasing
prevalence of comorbidities other than depression at the
time of T2DM diagnosis may reflect the increase in the
proportion of people diagnosed at a relatively early age
[37]. This could mean that people are diagnosed with
T2DM before they develop other comorbidities.
Our hierarchical clustering analysis showed that condi-
tions regarded as diabetes-concordant (stroke, atrial fib-
rillation, CKD, CHD, hypertension, PVD and heart
failure) tend to group together in all analysed groups.
Cancer has been linked with different condition groups,
depending on the analysed stratum. This may be due to
the fact that we grouped all types of cancer into one
condition. However, specific types of cancer may be
more prevalent in different groups and be linked with
the conditions sharing common risk factors. At the time
of the T2DM diagnosis, the clusters seem to follow an
expected pattern with lung diseases (asthma and COPD),
mental health conditions (depression and SMI) and vas-
cular conditions (PVD, CHD, stroke, atrial fibrillation
and heart failure) grouped together. However, the group-
ing becomes more complex after the diagnosis with con-
ditions needing different treatment and management
likely to occur together. These complexities highlight
the need for patient-centred approach. Furthermore,
greater emphasis is needed on preventative actions and
constant monitoring for conditions not closely related to
the ones already experienced by the patient.
Conclusion
Most people with T2DM have at least one other condi-
tion that can influence the self-management of diabetes
and its progression. We found a high prevalence of
T2DM-concordant conditions such as hypertension,
CHD and CKD as well as T2DM-discordant conditions
such as COPD and depression. The complexity of needs,
specific to the patients’ comorbidities patterns as well as
socio-economic situation, has to be considered when de-
veloping and providing comprehensive and precise care
for people with T2DM. With the growing prevalence of
T2DM [38], these complexities have to be taken into ac-
count when planning future care services, particularly
given the higher cost of treating people with multiple
conditions [39] and the lead times for developing appro-
priately skilled multi-disciplinary care teams. Further re-
search is needed to identify the best course of action for
treating people with multiple conditions, as recent re-
search shows that existing interventions are not particu-
larly effective for improving quality of life [40, 41].
Our analysis shows that cardiovascular conditions may
become less prevalent among people with T2DM; how-
ever, clinicians will have to identify and manage the
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rising burden of comorbid mental health problems. Cur-
rently, services targeting people with T2DM are geared
towards cardiovascular conditions. The growing burden
of mental health conditions will require the restructuring
of the services and workforce planning.
The cluster analysis showed that certain diseases are
more likely to occur together; however, the specific
grouping depends on the time after T2DM diagnosis.
Further research could explore how individual patients
experience the progression from no comorbidities to
groups of conditions affecting different parts of the body
and needing complex treatments.
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